Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

BACKGROUND: For metastatic colorectal cancer (mCRC) patients for whom at least 2 lines of previous standard therapies have failed, the prognosis is often unfavorable due to very limited subsequent treatment options. We sought to explore the efficacy of apatinib, an oral small-molecule vascular endot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Runzhi, Yang, Liu, Hu, Sheng, Yin, Zhusheng, Nie, Yanli, Xu, Hongli, Zhong, Yi, Zhu, Yuze, Liang, Xinjun, Xu, Huiting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848367/
https://www.ncbi.nlm.nih.gov/pubmed/35282086
http://dx.doi.org/10.21037/atm-22-77

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848367/
https://www.ncbi.nlm.nih.gov/pubmed/35282086
http://dx.doi.org/10.21037/atm-22-77

Ejemplares similares